A NOVEL APPROACHES ON OCULAR DRUG DELIVERY SYSTEM
The purpose of this review is giving a current update of the knowledge in this field of ocular drug delivery. The ocular drug delivery has been a major challenge to drug delivery scientists mainly due to its unique anatomy and physiology. One of the major problems encountered by the conventional ocular dosage forms include the rapid precorneal drug loss due to its nasolacrimal drainage, tear turnover and drug dilution resulting in poor bioavailability. These efforts lead to development of novel drug delivery dosage forms such as nanoparticles, liposome, ocuserts, and mucoadhesive formulations. Controlled drug delivery systems offer many advantages over conventional dosage forms in terms of improving drug bioavailability, reducing toxicity and decreasing dosage frequency. Designing noninvasive sustained drug delivery systems and exploring the feasibility of topical application to deliver drugs to the posterior segment may drastically improve drug delivery in the years to come.
Keywords: Ocular drug delivery, Eye, Conventional drug delivery, novel dosage forms, approaches.
2. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems recent advances. Prog Retin Eye Res. 1998; 17:33-58.
3. Gulsen D, Chauhan A, Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci. 2004; 45: 2342-2347.
4. Gaudana R, Ananthula HK, Parenky A, Mitra AK, Ocular drug delivery. AAPS J. 2010; 12:348-360.
5. Gaudana R, Jwala J, Boddu SH, Mitra AK, Recent perspectives in ocular drug delivery. Pharm Res. 2009; 26:1197-1216.
6. Schoenwald RD, Ocular drug delivery. Pharmacokinetic considerations. Clin Pharmacokinet, 1990; 18:255-269.
7. Kamel A, In vitro and in vivo evaluation of Pluronic F127 based ocular delivery system for timolol maleate, International Journal of Pharmaceutics, 2002; 24 (1): 47-55.
8. Saini, In situ gels a new trends in ophthalmic drug delivery systems, International Journal recent Advanced Pharmaceutical Research, 2015; 5 (3): 285-289.
9. Swapnil S, A Review on polymers used in novel in situ gel formulation for ocular drug delivery and their evaluation, Journal of biological and scientific opinion, 2003; 1(2): 132-137.
10. Pandya TP, Modasiya MK, Patel VM, Opthalmic in-situ gelling system, International Journal of Pharmacy & Life sciences, 2011; 2(5): 730-738.
11. Jitendra PK, Sharma A, Banik, Dixit S, A new trend ocular drug delivery system, International. Journal of Pharmaceutical. Sciences, 2011; 2(3): 720-744.
12. Nagyova B, Tiffany JM, Components responsible for the surface tension of human tears, Current Eye Research, 1999; 19(1): 4-11.
13. Jain R, Shastri P, Study of ocular drug delivery system using drug loaded liposomes, International Journal of Pharmaceutical Science Investigation, 2011; 1(1): 234-244.
14. Vandamme TF, Brobeck L, Poly (amid amine) dendrites as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropic amide, Journal of Control Release, 2005; 102: 23- 38.
15. Vandamme TF, Micro emulsions as ocular drug delivery systems recent development, Sch. Acad. J. Pharm., 2015; 4(7):340-346 346
16. Pignatello R, Flurbiprofen-loaded acrylate polymer nano suspensions for ophthalmic application, Biomaterials, 2002; 23: 3247- 3255.
17. Gariepy ER, Leroux GC, in situ-forming hydro gels review of temperature sensitive systems, European Journal of Pharmaceutics and Bio pharmaceutics, 2004; 58: 409-426.
18. Masteikova R, Chalupova Z, Sklubalova Z, Stimuli-sensitive hydrogels in controlled and sustained drug delivery, Medicina, 2003; 39: 19-24.
19. Tomme SRV, Storm G, Hennink EW, In situ gelling hydro gels for pharmaceutical and biomedical application, International Journal of Pharmaceutics, 2008; 355: 1-18.
20. Ravindra Reddy K, Ravi Shankar Yadav M, Sabitha Reddy P; Preparation and evaluation of Aceclofenac ophthalmic In situ gels, Journal of Chemical, Biological and Physical Sciences. 2011, 1(2): 289-298.
21. Katariya dhirajkumar champalal, Poddar Sushilkumar S, Current status of ophthalmic insitu forming hydrogel, International Journal of Pharma and Bio Sciences, 2012; 3(3): 372-388.
22. Lee SJ, He W, Robinson SB, Robinson MR, Csaky KG, Kim H. Evaluation of clearance mechanisms with transscleral drug delivery, Invest Ophthalmol Vis Sci, 2010; 51:5205-5212.
23. Schoenwald RD, Ocular drug delivery. Pharmacokinetic considerations, Clin Pharmacokinet, 1990; 18:255-269.
24. Vaka SR, Sammeta SM, Day LB, Murthy SN, Transcorneal iontophoresis for delivery of ciprofloxacin hydrochloride, Curr Eye Res, 2008; 33:661â€“667.
25. Gallarate M, Chirio D, Bussano R, Peira E, Battaglia L, Baratta F, Trotta M, Development of O/W nanoemulsions for ophthalmic administration of timolol, Int J Pharm, 2013;440:126â€“134.
26. Gebhardt BM, Varnell ED, Kaufman HE, Cyclosporine in collagen particles corneal penetration and suppression of allograft rejection, J Ocul Pharmacol Ther, 1995;11:509-517.
27. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L, Evaluation of ocular permeation enhancers, in vitro effects on corneal transport of four beta-blockers, and in vitro/in vivo toxic activity, Int J Pharm, 1996;142:103â€“113.
28. Van der Bijl P, van Eyk AD, Meyer D, Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea, 2001; 20:505-508.
29. Burgalassi S, Chetoni P, Monti D, Saettone MF, Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines, Toxicol Lett. 2001; 122:1-8.
30. Keister JC, Cooper ER, Missel PJ, Lang JC, Hager DF, Limits on optimizing ocular drug delivery, J Pharm Sci, 1991; 80:50â€“53.
31. Shen J, Gan L, Zhu C, Zhang X, Dong Y, Jiang M, Zhu J, Gan Y, Novel NSAIDs ophthalmic formulation flurbiprofen acetyl emulsion with low irritancy and improved anti-inflammation effect, Int J Pharm, 2011;412:115-122.
32. Vandamme TF, Microemulsions as ocular drug delivery systems: recent developments and future challenges, Prog Retin Eye Res, 2002; 21:15-34.
33. Liang H, Brignole-Baudouin F, Rabinovich Guilatt L, Mao Z, Riancho L, Faure MO, Warnet JM, Lambert G, Baudouin C, Reduction of quaternary ammonium induced ocular surface toxicity by emulsions: an in vivo study in rabbits, Mol Vis, 2008;14:204â€“216.
34. Tajika T, Isowaki A, Sakaki H, Ocular distribution of difluprednate ophthalmic emulsion 0. 05% in rabbits, J Ocul Pharmacol Ther, 2011; 27:43-49.
35. Dwivedi C, Sahu R, Tiwari S, Satapathy T, Roy A. Role of liposome in novel drug delivery system. Journal of Drug Delivery and Therapeutics, 2014; 4(2):116-129. doi:10.22270/jddt.v4i2.768
36. Gray C, Systemic toxicity with topical ophthalmic medications in children, Paediatric and Perinatal Drug Therapy, 2006; 7:23â€“29.
37. Prajapati S, Maurya S, Das M, Tilak V, Verma K, & Dhakar R. Dendrimers in drug delivery, diagnosis and therapy: basics and potential applications. Journal of Drug Delivery and Therapeutics, 2016; 6(1):67-92. doi:10.22270/jddt.v6i1.1190
38. Kang Derwent JJ, Mieler WF, Thermo responsive hydro gels as a new ocular drug delivery platform to the posterior segment of the eye, Trans Am Ophthalmol Soc, 2008;106:206â€“213.
39. Gupta H, Aqil M. Contact lenses in ocular therapeutics, Drug Discov Today, 2012; 17:522-527.
40. Shah D, Patel B, Shah C. Nanosuspension technology: a innovative slant for drug delivery system and permeability enhancer for poorly water soluble drugs. Journal of Drug Delivery and Therapeutics, 2015; 5(1):10-23. doi:10.22270/jddt.v5i1.995
41. Kim J, Chauhan A. Dexamethasone transport and ocular delivery from poly hydroxyethyl methacrylate gels, Int J Pharm, 2008; 353:205-222.
42. Chauhan Meenakshi K., Yenamandra Jahnavi, Management of glaucoma: effective drug delivery via Niosomes, Journal of Drug Delivery and Therapeutics. 2016; 6(6):48-53 DOI: http://dx.doi.org/10.22270/jddt.v6i6.1313
43. Tham Y C, Li X, Wong T Y, Quigley A H, Aung T, Cheng C Y, Global prevalence of glaucoma and projections of glaucoma burden through 2040 A systematic review and meta-analysis, Ophthalmology, 2014, 121(11), 2081-2090
44. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G, Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery, J Drug Target, 2011;19:409â€“417.
45. Agnihotri SM, Vavia PR, Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application, Nanomedicine, 2009; 5:90-95.
46. Bhatta RS, Chandasana H, Chhonker YS, Rathi C, Kumar D, Mitra K, Shukla PK. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies, Int J Pharm, 2012;432:105-112.
47. Law SL, Huang KJ, Chiang CH, Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release. 2000; 63:135â€“140.
48. Rajoria G, Gupta A, In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery, AJPTR, 2012; 2:24â€“53.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).